Non-invasive Prenatal Testing Market is Predicted to Witness 10.9% CAGR till 2028
by Sara James Research AnalystThe
global Non
Invasive Prenatal Testing Market size is anticipated to reach USD 6.5
billion by 2028 registering a CAGR of 10.9%, according to a new report by Grand
View Research, Inc. High adoption and demand for early non-invasive prenatal
testing (NIPT) coupled with improvements in reimbursement scenario are among
the factors driving the market.
The
use of invasive techniques of prenatal testing, such as chorionic villus
sampling and amniocentesis, can lead to issues, such as miscarriage. This has
led to a decline in the use of these procedures and high demand for tests that
are more efficient, non-invasive, and safe. Furthermore, non-invasive fetal
tests have a lower failure and false-positive rate, which has resulted in a
considerable increase in uptake of non-invasive tests in the last few years.
The
non-invasive prenatal testing market is highly saturated with the existing key
players. Companies are forming partnerships and collaborations to maintain a
stable position in the market. For instance, in August 2020, Eurofins
Scientific announced an agreement with Noritsu Koki Co., Ltd. for the
acquisition of GeneTech Inc., one of the pioneering NIPT developers in Japan.
With this acquisition, Eurofins Scientific is set to strengthen its presence in
the Japanese NIPT market.
Related Press
Release@ Non-invasive
Prenatal Testing Market Report
Non-invasive Prenatal Testing Market Report Highlights
- The 13-24
weeks gestation period segment accounted for the largest revenue share in
2020 owing to the presence of a maximum number of tests carried out in
this phase of pregnancy
- NIPT for
high- & average-risk pregnancy led the market owing to the presence of
favorable payer reimbursement policies in this segment
- Next-Generation
Sequencing (NGS) is estimated to be the largest as well as the fastest-growing
technology segment from 2021 to 2028, as NGS is the most commonly used
method for NIPT
- The
diagnostic laboratories end-use segment held the largest revenue share in
2020 and will expand further at the fastest CAGR from 2021 to 2028 due to
the rising number of diagnostic laboratories across the globe that offer
NIPT
- Asia Pacific
is expected to register the fastest year-on-year growth owing to the
gradually increasing average maternal age and rising incidence of
chromosomal aneuploidies
- One of the
key trends followed by market participants includes licensing of the test
to other labs and generating significant revenue by collecting royalty
payments
Sponsor Ads
Created on May 3rd 2021 07:13. Viewed 290 times.